[1] E. Nordborg, C. Nordborg. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment, Rheumatology, Volume 42, Issue 3, March 2003, Pages 413–421, https://doi.org/10.1093/rheumatology/keg116
[2] Piggott K, Biousse V, Newman NJ, Goronzy JJ, Weyand CM. Vascular damage in giant cell arteritis. Autoimmunity. 2009;42(7):596‐604. doi:10.1080/08916930903002495
[3] Charlton R. Optimal management of giant cell arteritis and polymyalgia rheumatica. Ther Clin Risk Manag. 2012;8:173‐179. doi:10.2147/TCRM.S13088
[4] Baig IF, Pascoe AR, Kini A, Lee AG. Giant cell arteritis: early diagnosis is key. Eye Brain. 2019;11:1‐12. Published 2019 Jan 17. doi:10.2147/EB.S170388
[5] Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Annals of the Rheumatic Diseases 2010;69:780-781.
[6] Marília A. Dagostin and Rosa M.R. Pereira (January 28th 2020). Giant Cell Arteritis: Current Advances in Pathogenesis and Treatment [Online First], IntechOpen, DOI: 10.5772/intechopen.91018. Available from: https://www.intechopen.com/online-first/giant-cell-arteritis-current-advances-in-pathogenesis-and-treatment
[7] Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2):129‐135. doi:10.1212/01.wnl.0000316802.35974.34
[8] Weyand, C., Goronzy, J. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 9, 731–740 (2013). https://doi.org/10.1038/nrrheum.2013.161
[9] Brekke LK, Fevang BT, Myklebust G. Increased Incidence of Giant Cell Arteritis in Urban Areas?. J Rheumatol. 2019;46(3):327‐328. doi:10.3899/jrheum.180714
https://www.ncbi.nlm.nih.gov/books/NBK459376/
[10] Andersson, R, Weinar, A. Integration policies : Sweden country report. Migration Policy Centre, INTERACT Research Report, Country Reports. Updated 2014.
Retrieved from Cadmus, European University Institute Research Repository, at: http://hdl.handle.net/1814/32656
[11] Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, PerezAlvarez R, Gonzalez-Juanatey C, Sanchez-Andrade A, Martin J, Llorca J (2007) Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 86:61–68
[12] Petursdottir V, Johansson H, Nordborg E, Nordborg C (1999) The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatol (Oxf) 38:1208–1212
[13] Nordborg C, Johansson H, Petursdottir V, Nordborg E (2003) The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population. Rheumatol (Oxf) 42:549–552
[14] Summary of Population Statistics 1960-2019. Statistics Sweden website. Updated March 19, 2020. Accessed May 27, 2020. https://www.scb.se/en/finding-statistics/statistics-by-subject-area/population/population-composition/population-statistics/pong/tables-and-graphs/yearly-statistics--the-whole-country/summary-of-population-statistics/
[15] Foreign citizens by country of citizenship, age and sex. Year 1973-2019. Statistics Sweden website. Accessed May 27, 2020.
http://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101F/UtlmedbR/?rxid=b83e5bbd-958a-4655-aa40-486ba2ca09a3
[16] Moore, H. Immigration in Denmark and Norway: Protecting Culture or Protecting Rights? Scandinavian Studies, 2010;82(3), 355-364. Retrieved May 28, 2020, from www.jstor.org/stable/25769037
[17] Richard A. Watts, 2. Epidemiology of giant cell arteritis: a critical review, Rheumatology, Volume 53, Issue suppl_2, July 2014, Pages i1–i2, https://doi.org/10.1093/rheumatology/keu183
[18] Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol. 2008;35(1-2):88‐95. doi:10.1007/s12016-008-8075-0
[19] Palomino-Morales RJ, Vazquez-Rodriguez TR, Torres O, et al. Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis. Arthritis Res Ther. 2010;12(2):R51. doi:10.1186/ar2962
[20] Brown, P. Chapter 1: Citizen-Science Alliances and Health Social Movements. In: Brown, P., Toxic Exposures: Contested Illnesses and the Environmental Health Movement.
New York: Columbia University Press, 2007: 5.
[21] Vyvey M. Steroids as pain relief adjuvants. Can Fam Physician. 2010;56(12):1295‐e415.
[22] Ben-Shabat N, Tiosano S, Shovman O, et al. Mortality among patients with giant-cell arteritis: A large-scale population-based cohort study [published online ahead of print, 2019 Dec 15]. J Rheumatol. 2019;jrheum.190927. doi:10.3899/jrheum.190927
[23] Bisgård C, Sloth H, Keiding N, Juel K. Excess mortality in giant cell arteritis. J Intern Med. 1991;230(2):119‐123. doi:10.1111/j.1365-2796.1991.tb00418.x
[24] Lillian Bara, Janet E Pope, Priscila Pequeno, Farah E Saxena, Mary Bell, Derek Haaland, Jessica Widdifield, Incidence and prevalence of giant cell arteritis in Ontario, Canada, Rheumatology, , keaa095, https://doi.org/10.1093/rheumatology/keaa095
[25] Crow RW, Katz BJ, Warner JE, et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci. 2009;64(3):365‐369. doi:10.1093/gerona/gln030
[26] Uddhammar A, Eriksson A-L, Nyström L, et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol. 2002;29(4):737–42.